利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

169 条记录 (耗时 0.038 秒)

    LIPASES FOR PHARMACEUTICAL USE
    6.
    发明公开
    LIPASES FOR PHARMACEUTICAL USE 审中-公开
    LIPASEN ZUR PHARMAZEUTISCHEN VERWENDUNG

    公开(公告)号：EP1896577A2

    公开(公告)日：2008-03-12

    申请号：EP06742471.3

    申请日：2006-06-16

    申请人： Novozymes A/S ,  Solvay Pharmaceuticals GmbH

    发明人： SVENDSEN, Allan ,  BORCH, Kim ,  GREGORY, Peter, Colin

    IPC分类号： C12N9/20 ,  A61K38/54 ,  A61K38/46

    CPC分类号： C12N9/20

    摘要： The pharmaceutical use of lipases related to a variant of the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 1, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have an improved efficacy in vivo, are stable against protease-degradation, and/or are stable in the presence of bile salts.

    摘要翻译： 与包含SEQ ID NO：1的氨基酸1-269的Thermomyces lanuginosus（Humicola lanuginosa）脂肪酶的变体相关的脂肪酶的药物用途，任选地与蛋白酶和/或淀粉酶组合。 医学适应症的例子有：消化系统疾病，胰腺外分泌功能不全（PEI），胰腺炎，囊性纤维化，I型糖尿病和/或II型糖尿病的治疗。 本发明的脂肪酶在体内具有改善的功效，对蛋白酶降解是稳定的，和/或在胆汁盐存在下是稳定的。

    PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RENAL DYSFUNCTION
    7.
    发明授权
    PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RENAL DYSFUNCTION 有权
    药物组合物肾功能不全的治疗

    公开(公告)号：EP1687006B1

    公开(公告)日：2007-11-14

    申请号：EP04818828.8

    申请日：2004-11-15

    申请人： Solvay Pharmaceuticals GmbH

    发明人： THORMAEHLEN, Dirk ,  HOCHER, Berthold ,  WALDECK, Harald

    IPC分类号： A61K31/55 ,  A61P13/12 ,  A61P43/00

    CPC分类号： A61K31/55

    摘要： The present invention relates to a novel use of benzazepine-N-acetic acid derivatives which contain an oxo-group in the α-position to the nitrogen atom and are substituted in position 3 by a 1- (carboxyalkyl)cyclopentylcarbonylamino radical, and/or of their salts and biolabile esters, and/or of physiologically acceptable solvates thereof, in larger mammals and particularly in humans, preferably human patients having diabetes, and to the production of pharmaceutical compositions and products suitable for the novel treatment. The invention particularly relates to the treatment and/or prophylaxis of renal dysfunction, disease or disorder, preferably in diabetic patients, but in a broader sense also in patients with syndrome X or in particular in patients with a renal dysfunction, disease and /or disorder, which patients are in addition hypertensive, obese, hyperglycemic and/or subject to metabolic disorder.